ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Integrin alpha 11 beta 1

Integrin alpha 11 beta 1

概要

Name:Leukocyte adhesion glycoprotein LFA-1 alpha
Target Synonym:Integrin, Alpha L (Antigen CD11A (P180), Lymphocyte Function-Associated Antigen 1; Alpha Polypeptide),Leukocyte adhesion glycoprotein LFA-1 alpha chain,ITGAL,LFA-1A,Integrin Subunit Alpha L,CD11 antigen-like family member A,Integrin, Alpha L (Antigen CD11A (P180), Lymphocyte Function-Associated Antigen 1,Alpha Polypeptide),Lymphocyte Function-Associated Antigen 1, Alpha Polypeptide,CD11A,Integrin Gene Promoter,Antigen CD11A (P180),LFA-1 Alpha,LFA-1,LFA1A,CD11a Antigen,Integrin alpha-L,Leukocyte
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

IT1-C52W9-ELISA
 Integrin alpha 11 beta 1 ELISA

Immobilized Native Human Collagen I protein at 10 μg/mL (100 μL/well) can bind Canine ITGA11&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-C52W9) with a linear range of 0.078-5 μg/mL (QC tested).

IT1-C53W3-ELISA
 Integrin alpha 11 beta 1 ELISA

Immobilized Native Human Collagen IV Protein at 10 μg/mL (100 μL/well) can bind Cynomolgus ITGA1&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-C53W3) with a linear range of 0.156-1.25 μg/mL (QC tested).

Synonym Name

Integrin alpha 11 beta 1,ITGA11&ITGB1

Background

Integrin alpha 11 beta 1 is a receptor for collagen. The alpha11 cDNA encodes a mature protein with a large 1120-residue extracellular domain that contains an I-domain of 207 residues and is linked by a transmembrane domain to a short cytoplasmic domain of 24 amino acids. The deduced alpha11 protein shows the typical structural features of integrin alpha-subunits and is similar to a distinct group of alpha-subunits from collagen-binding integrins.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Odulimomab Approved Immunotech SAS Antilfa France Graft vs Host Disease; Rejection of renal transplantation null 1997-01-01 Rejection of renal transplantation; Graft vs Host Disease Details
Odulimomab Approved Immunotech SAS Antilfa France Graft vs Host Disease; Rejection of renal transplantation null 1997-01-01 Rejection of renal transplantation; Graft vs Host Disease Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
VVN-001 VVN001; VVN-001 Phase 3 Clinical VivaVision Biotech Inc Dry Eye Syndromes; Xerophthalmia Details
P-28-R P-28- R Phase 1 Clinical Canimguide Therapeutics Head and Neck Neoplasms Details
VVN-001 VVN001; VVN-001 Phase 3 Clinical VivaVision Biotech Inc Dry Eye Syndromes; Xerophthalmia Details
P-28-R P-28- R Phase 1 Clinical Canimguide Therapeutics Head and Neck Neoplasms Details

This web search service is supported by Google Inc.

totopphone